The aryl hydrocarbon receptor is downregulated in MASLD while its activation attenuates steatosis in human hepatocytes through an IGFBP1-associated pathway
4 affiliations
- 1CIBEREHD, Instituto de Salud Carlos III, Madrid, Spain
- 2Experimental Hepatology Joint Research Unit. Health Research Institute La Fe, Valencia, Spain
- 3Servicio de Cirugía General y Aparato Digestivo, Hospital Universitario Dr. Peset, Valencia, Spain
- 4Biochemistry and Molecular Biology Department, Universitat de València, Valencia, Spain
Abstract
Metabolic dysfunction–associated steatotic liver disease (MASLD) represents a growing global health concern; however, its multiple pathogenic mechanisms remain incompletely understood. The role of the aryl hydrocarbon receptor (AHR) in MASLD is controversial, as it has been described as either pro- or anti-steatotic depending on the experimental context. Through whole-genome expression profiling and RT-qPCR analysis of human liver biopsies from two independent MASLD patient cohorts, we demonstrate that AHR expression and its canonical activity—assessed by CYP1A1 mRNA levels—are inversely correlated with hepatic steatosis. The role of AHR was further investigated in cultured human Upcyte® hepatocytes from different donors treated with a 2:1 oleate:palmitate mixture (0.6 mM) to induce steatosis, in combination with the exogenous AHR agonist β-naphthoflavone (BN, 25 µM) or the endogenous agonist 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE, 25 µM). Activation of AHR resulted in a statistically significant reduction of intracellular lipid levels, as determined by triglyceride quantification and AdipoRed staining. Microarray analysis of AHR-activated human hepatocytes identified IGFBP1 as a robustly induced target gene. Consistently, IGFBP1 expression was diminished in the livers of both MASLD cohorts and positively correlated with AHR expression levels. Furthermore, treatment of human hepatocytes with recombinant IGFBP1, alone or in combination with IGF1, reduced lipid accumulation, supporting IGFBP1 as a potential downstream effector within the anti-steatotic AHR pathway. Collectively, these findings support a role for AHR and its target IGFBP1, as key negative regulators of hepatic lipid accumulation in human hepatocytes and suggest that activation of this pathway may be taken into account in the therapeutic approaches for MASLD.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s00204-026-04513-w.
Related
- Killer Cell Activating Receptor–Associated Protein Exacerbates Intestinal Inflammation Through Promoting Kynurenine–Aryl Hydrocarbon Receptor–Dependent Neutrophil Activation in Ulcerative Colitis
- Apigenin Attenuates Lipopolysaccharide-Induced Endothelial Activation and Injury-Associated Phenotypes in Human Umbilical Vein Endothelial Cells
- Ginsenoside Re attenuates severe acute pancreatitis-associated acute lung injury by inhibiting pancreatic necroptosis-driven cfDNA release and pulmonary cGAS-STING activation
- Emerging links between gut dysbiosis, aryl hydrocarbon receptor activation, and Parkinson’s disease
- Wildfire-Emitted Particulate Matter Induces Ovarian Hyperandrogenism through Aryl Hydrocarbon Receptor Activation
BibTeX
@article{pozomedina2026aryl,
title = {{The aryl hydrocarbon receptor is downregulated in MASLD while its activation attenuates steatosis in human hepatocytes through an IGFBP1-associated pathway}},
author = {Marta del Pozo-Medina and Polina Soluyanova and Eugenia Pareja and Marta Moreno-Torres and Ramiro Jover},
journal = {Archives of Toxicology},
year = {2026},
month = jul,
doi = {10.1007/s00204-026-04513-w},
url = {https://doi.org/10.1007/s00204-026-04513-w},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The aryl hydrocarbon receptor is downregulated in MASLD while its activation attenuates steatosis in human hepatocytes through an IGFBP1-associated pathway
AU - Marta del Pozo-Medina
AU - Polina Soluyanova
AU - Eugenia Pareja
AU - Marta Moreno-Torres
AU - Ramiro Jover
PY - 2026
DA - 2026/07/22
JO - Archives of Toxicology
DO - 10.1007/s00204-026-04513-w
UR - https://doi.org/10.1007/s00204-026-04513-w
AB - Metabolic dysfunction–associated steatotic liver disease (MASLD) represents a growing global health concern; however, its multiple pathogenic mechanisms remain incompletely understood. The role of the aryl hydrocarbon receptor (AHR) in MASLD is controversial, as it has been described as either pro- or anti-steatotic depending on the experimental context. Through whole-genome expression profiling and RT-qPCR analysis of human liver biopsies from two independent MASLD patient cohorts, we demonstrate that AHR expression and its canonical activity—assessed by CYP1A1 mRNA levels—are inversely correlated with hepatic steatosis. The role of AHR was further investigated in cultured human Upcyte® hepatocytes from different donors treated with a 2:1 oleate:palmitate mixture (0.6 mM) to induce steatosis, in combination with the exogenous AHR agonist β-naphthoflavone (BN, 25 µM) or the endogenous agonist 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE, 25 µM). Activation of AHR resulted in a statistically significant reduction of intracellular lipid levels, as determined by triglyceride quantification and AdipoRed staining. Microarray analysis of AHR-activated human hepatocytes identified IGFBP1 as a robustly induced target gene. Consistently, IGFBP1 expression was diminished in the livers of both MASLD cohorts and positively correlated with AHR expression levels. Furthermore, treatment of human hepatocytes with recombinant IGFBP1, alone or in combination with IGF1, reduced lipid accumulation, supporting IGFBP1 as a potential downstream effector within the anti-steatotic AHR pathway. Collectively, these findings support a role for AHR and its target IGFBP1, as key negative regulators of hepatic lipid accumulation in human hepatocytes and suggest that activation of this pathway may be taken into account in the therapeutic approaches for MASLD. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s00204-026-04513-w.
SN - 0340-5761
SN - 1432-0738
ER -